[Final results of cooperative studies of dicarbamine used as a hemoprotector in combination chemotherapy for cancer].
Bychkov
M B
MB
Besova
N S
NS
Topchieva
S V
SV
Verebnikova
N V
NV
Gorbunova
V A
VA
Garin
A M
AM
Chitiia
L V
LV
Borisov
V I
VI
Gurov
S N
SN
Gershanovich
M L
ML
Filatova
L V
LV
Makhnova
E V
EV
Raĭkhlin
N T
NT
Treshchalina
E M
EM
Sitdikova
S M
SM
Nebol'sin
V E
VE
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D001853:Bone Marrow / Q000187:drug effects*; D002208:Caproates; D003520:Cyclophosphamide / Q000009:adverse effects; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives; D004317:Doxorubicin / Q000009:adverse effects; D005260:Female; D006397:Hematinics / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007970:Leukopenia / Q000139:chemically induced / Q000188:drug therapy; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced / Q000188:drug therapy; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome; D000093542:Gemcitabine
D002208:Caproates; D006397:Hematinics; D007093:Imidazoles; D003841:Deoxycytidine; C539419:pentanedioic acid imidazolyl ethanamide; D004317:Doxorubicin; D003520:Cyclophosphamide; D000093542:Gemcitabine